Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Last Updated: Friday, July 17, 2026

Heavily pretreated patients with relapsed or refractory HL who received fludarabine-based lymphodepletion followed by CD30 CAR-Ts had a high rate of durable responses with an excellent safety profile, highlighting the feasibility of extending CAR-T cell therapies beyond canonical B-cell malignancies.

Journal of Clinical Oncology

Frontiers in Immunotherapy

Smart control of CAR-T cells: Emerging strategies for safer and more effective cancer immunotherapy

Molecular Therapy

CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors

Nature Medicine

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: A phase 1 study

Frontiers in Oncology

Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: A systematic review and meta-analysis

Journal of Translational Medicine

Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer

Trends in Cancer

In vivo CAR T cell engineering: Design principles and open questions

Blood Cancer Discovery

Multiomic and longitudinal dissection of immune dynamics associated with parkinsonism after ciltacabtagene autoleucel therapy

Blood Advances

Non-ICANS neurologic toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

Molecular Immunology

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions

Cancer

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

CAR T-Cell Therapy Resource Center